Revvity price target raised to $120 from $115 at TD Cowen

TD Cowen analyst Dan Brennan raised the firm’s price target on Revvity (RVTY) to $120 from $115 and keeps a Buy rating on the shares. The firm said commentary on its conference call supported the thesis that signs of Pharma/A&G demand improvement are growing, underlying software strength intact, core Dx performing well, management confidence remains high in notable expected margin ramp (via cost actions), and now China ImmunoDx divestiture removes a key risk